linagliptin

FDA Drug Profile — Tradjenta

linagliptin is listed in the FDA National Drug Code directory with 5 NDC codes, marketed under brand name including Tradjenta. Available dosage forms: tablet, film coated, powder.

Drug details

Generic Name
linagliptin
Brand Names
Tradjenta
Application Number
NDA201280
Sponsor
Boehringer Ingelheim Pharmaceuticals, Inc.
NDC Codes
5
Dosage Forms
TABLET, FILM COATED, POWDER
Routes
ORAL
Active Ingredients
LINAGLIPTIN

Indications and Usage

1 INDICATIONS AND USAGE TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . TRADJENTA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 ) Limitations of Use • Not recommended in patients with type 1 diabetes mellitus as it would not be effective ( 1 ) • Has not been studied in patients with a history of pancreatitis ( 1 ) Limitations of Use TRADJENTA is not recommended in patients with type 1 diabetes mellitus as it would not be effective. TRADJENTA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using TRADJENTA [see Warnings and Precautions (5.1) ].

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.